Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 18

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 18
---
 stockholders were combined into one share of common stock. Our authorized common stock remained at 60,000,000 shares following the stock split. We issued an additional 77 shares as a result of rounding up fractional shares related to the reverse stock split.

On June 2, 2025, a second patient was treated with the Hemopurifier at GenesisCare North Shore Hospital in Sydney, Australia. The
patient was treated with the Aethlon Hemopurifier for 4 hours in a single day and tolerated the procedure without complications. The
patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

| 7 |

Intellectual Property

We currently own or have license
rights to a number of U.S. and foreign patents and patent applications and endeavor to continually improve our intellectual property
position. We consider the protection of our technology, whether owned or licensed, to the exclusion of use by others, to be vital to
our business. While we intend to focus primarily on patented or patentable technology, we also rely on trade secrets, unpatented property,
know-how, regulatory exclusivity, patent extensions and continuing technological innovation to develop our competitive position. We also
own certain trademarks.

Our success depends in large
part on our ability to protect our proprietary technology, including the Hemopurifier product platform, and to operate without infringing
the proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentiality
agreements, licensing agreements and other agreements, to establish and protect our proprietary rights. Our success also depends, in
part, on our ability to avoid infringing patents issued to others. If we were judicially determined to be infringing on any third-party
patent, we could be required to pay damages, alter our products or processes, obtain licenses or cease sales of products or certain activities.

To protect our proprietary medical
technologies, including the Hemopurifier product platform and other scientific discoveries, we have a portfolio of over 32 issued patents
and pending applications worldwide. We currently have three issued U.S. patents and 14 issued patents in countries outside of the United
States. In addition, we have 15 patent applications pending worldwide related to our Hemopurifier product platform and other technologies.
We are seeking additional patents on our scientific discoveries.

It is possible that our pending
patent applications may not result in issued patents, that we will not develop